Japan Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Users (hospitals clinics, diagnostic centers, academic research institutes) - Forecast to 2035

Japan Dry Age-Related Macular Degeneration (AMD) Market Overview

As per MRFR analysis, the Japan Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 275.0 (USD Million) in 2023. The Japan Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 300.0(USD Million) in 2024 to 900.0 (USD Million) by 2035. The Japan Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 10.503% during the forecast period (2025 - 2035).

Key Japan Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted

The Japan Dry Age-Related Macular Degeneration (AMD) Market is witnessing significant trends driven by an increasingly aging population, which is a primary market driver. With nearly a third of Japan's population being over 65 years old, there is a growing prevalence of age-related eye diseases, including dry AMD. This demographic shift is prompting healthcare authorities and providers to focus on early diagnosis and preventative measures, emphasizing regular eye examinations for senior citizens. 

Additionally, advancements in technology and research have led to innovative treatment options, including new pharmaceuticals aimed at managing the symptoms and progression of dry AMD.There is a greater focus on education and awareness, which has already given many different market players a chance to interact with patients and educational campaigns for health professionals. Now, there is more interest in genetic testing and personalized medicine opportunities for AMD patients. Many businesses are now starting to implement targeted therapies that modify treatment on the basis of genetic makeup. The growth in collaboration between ophthalmologists and other sectors has significantly improved the innovation in treatments.

Clinical trials focusing on new drug formulations and delivery systems are on the rise, aiming to enhance efficacy and minimize side effects. Furthermore, the Japanese government's initiatives to promote healthcare technology adoption are likely to support advancements in diagnostic tools and treatment protocols for AMD. This collaborative approach in the healthcare sector exemplifies the commitment to addressing AMD's challenges and improving patient outcomes in Japan.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Japan Dry Age-Related Macular Degeneration (AMD) Market Drivers

Aging Population in Japan

Japan has one of the oldest populations in the world, with over 28% of its citizens aged 65 and older, as reported by the Japan Statistical Yearbook. This demographic shift drives the prevalence of age-related disorders, including dry age-related macular degeneration (AMD). Consequently, the increasing number of older adults is significantly impacting the Japan Dry Age-Related Macular Degeneration (AMD) Market Industry, resulting in a growing demand for effective treatment and management options for AMD.The Ministry of Health, Labour and Welfare has also observed that the incidence of visual impairments, such as AMD among the elderly, is predicted to rise by over 40% in the next decade, highlighting an urgent need for medical advancements and healthcare services tailored to this age group. With this rising demand, the industry is expected to see significant growth as healthcare providers and pharmaceutical companies invest in research and development of innovative therapeutic options.

Increasing Awareness and Early Detection

There has been a concerted effort in Japan to increase awareness regarding dry AMD and the importance of early detection and treatment. Campaigns led by organizations such as the Japan Eye Institute are pushing for regular eye check-ups among older adults. An increase in the number of routine eye examinations is expected to lead to earlier diagnoses of AMD. Recent data indicates that, due to improved awareness initiatives, more than 30% of the elderly population is getting regular eye check-ups, as opposed to only about 15% a decade ago.This surge in awareness directly contributes to growth in the Japan Dry Age-Related Macular Degeneration (AMD) Market Industry, as earlier detection typically translates to a higher likelihood of effective treatment and management, consequently boosting the market's value.

Advancements in Treatment Options

Innovations in the development of treatment options for dry AMD are on the rise, with research being spearheaded by reputable pharmaceutical companies within Japan, such as Takeda Pharmaceutical Company. Recent advancements in therapies, including intravitreal injections and oral medications aimed at slowing disease progression, have shown promising results in clinical trials. This progress is vital as the Japanese Ministry of Health has reported that about 1.5 million people suffer from some form of AMD, indicating a large patient pool that can benefit from these therapies.The continuous innovation in treatment methods and the approval of new medications are crucial for driving the Japan Dry Age-Related Macular Degeneration (AMD) Market Industry forward, as they provide new avenues for managing the condition and improving the quality of life for patients.

Japan Dry Age-Related Macular Degeneration (AMD) Market Segment Insights

Dry Age-Related Macular Degeneration (AMD) Market Stage Insights

The Japan Dry Age-Related Macular Degeneration (AMD) Market shows a clear segmentation based on the stage of the disease, which is critical for understanding patient needs and treatment approaches tailored to each progression level. In Japan, where the aging population is rapidly increasing, the prevalence of early age-related macular degeneration has become a priority for healthcare providers and policymakers. This stage, often characterized by the presence of drusen, plays a pivotal role in shaping intervention strategies, as early detection is essential for effective management and slowing disease progression.Intermediate age-related macular degeneration marks a transition where patients exhibit greater visual disturbances, creating significant demands on the healthcare system for timely and appropriate treatment. It is during this stage that the focus on innovative therapies and clinical trials is particularly robust, aiming to prevent further deterioration of vision. 

Late age-related macular degeneration is the most serious stage, typically leading to severe vision loss, thereby increasing the urgency for advanced therapies and rehabilitation services.With the Japan Dry Age-Related Macular Degeneration (AMD) Market challenging healthcare entities to adapt to the needs of a growing patient demographic, the different stages inform various market growth drivers. Recognizing the shifting landscape defined by risk factors like genetics, diet, and lifestyle habits offers opportunities for targeted educational campaigns aimed at enhancing early diagnosis and treatment adherence. 

Moreover, advancements in diagnostics and therapeutic areas are becoming increasingly significant in addressing the challenges posed by the disease's progression across its different stages.The multi-faceted nature of this segment underscores the importance of comprehensive, stage-oriented strategies to address the evolving needs of the population, especially in urban centers where healthcare infrastructure is more developed. 

Insights drawn from the Japan Dry Age-Related Macular Degeneration (AMD) Market statistics reveal that as public awareness rises and healthcare initiatives expand, collaboration among stakeholders becomes essential for optimizing resource allocation and enhancing patient outcomes. The strategic focus on the stages of age-related macular degeneration not only drives research and development in the sector but also consolidates efforts towards effective care models that can significantly impact the quality of life for aging individuals.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights

The Japan Dry Age-Related Macular Degeneration (AMD) Market reflects a notable correlation between age demographics and the prevalence of this eye condition, particularly among older populations. Individuals above 75 years significantly contribute to market development, often requiring specialized treatments and care due to the higher incidence of vision loss associated with AMD in this age group. Meanwhile, those above 60 years also present substantial demand, as they are increasingly diagnosed with early symptoms of dry AMD, necessitating regular monitoring and therapeutic interventions.Furthermore, the above 40 years age group is becoming more significant as awareness of AMD grows, prompting early screening and preventive measures.

 With an aging population in Japan, supported by government initiatives emphasizing eye health, the market is poised for growth driven by the needs of these age brackets. The prevalence in these segments not only highlights the urgency of addressing AMD but also opens opportunities for innovation in treatment and care solutions tailored to the specific needs of each group. The Japan Dry Age-Related Macular Degeneration (AMD) Market statistics indicate that addressing these age-related challenges is fundamental for advancing ocular healthcare in the country.

Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights

The Japan Dry Age-Related Macular Degeneration (AMD) Market, particularly in the realm of Diagnosis and Treatment, plays a crucial role in addressing the growing prevalence of this age-related condition. The rising number of elderly individuals in Japan, coupled with increased awareness and advances in diagnostic technologies, is propelling market growth. The diagnosis segment focuses on early detection through innovative imaging techniques and screening processes that allow for timely intervention, which is pivotal in managing the disease's progression.Meanwhile, treatment options are evolving rapidly, with a strong emphasis on developing effective therapies that can enhance visual outcomes for patients. Comprehensive approaches often blend pharmacological treatments with lifestyle modifications tailored to individual patient needs, addressing both physical and emotional aspects of care. 

This dual focus on diagnosis and treatment not only aims to improve patient’s quality of life but also highlights the significance of ongoing research and development in the sector. In Japan, government initiatives and healthcare policies further support advancements in this area, fostering an environment conducive to growth and innovation in Dry AMD management.With a significant demographic shift towards an aging population, the Diagnosis and Treatment segment in the Japan Dry Age-Related Macular Degeneration (AMD) Market is expected to continue evolving as a vital component of the healthcare landscape.

Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights

The Route of Administration segment within the Japan Dry Age-Related Macular Degeneration (AMD) Market is crucial as it impacts efficacy and patient compliance significantly. In Japan, the increasing prevalence of AMD has driven demand for various administration methods, which include oral medications and injectables. Oral administration is often preferred due to ease of use, allowing for improved patient adherence to treatment regimens, particularly among the elderly demographic that constitutes a large portion of AMD patients. Conversely, injectables play a pivotal role in delivering targeted therapies with potentially faster results, making them significant in treating advanced cases of AMD.The development of innovative injectable therapies has contributed to this route’s dominance in clinical settings. 

Furthermore, advancements in drug formulation and delivery systems are expected to enhance these administration routes, with a focus on improving treatment outcomes. The Japanese healthcare system is keen on integrating efficient and effective administration methods, which aligns with the growing market trends where patient-centric approaches are increasingly prioritized. 

This segment's growth is supported by ongoing research, development initiatives, and a healthcare environment that fosters innovation in treatment approaches for AMD.Thus, the Route of Administration segment is not only vital for standard practices in Japan but also for the strategic development of the industry moving forward.

Dry Age-Related Macular Degeneration (AMD) Market End Users Insights

The Japan Dry Age-Related Macular Degeneration (AMD) Market reflects a diverse landscape, particularly within the End Users segment, which includes hospitals clinics, diagnostic centers, and academic research institutes. Hospitals and clinics play a crucial role in the management and treatment of AMD, providing essential services that cater to the increasing aging population in Japan, known for having one of the highest life expectancies globally. 

Diagnostic centers are also significant, as they employ advanced imaging techniques crucial for early detection and monitoring of the disease, contributing to better patient outcomes.Academic and research institutes are instrumental in driving innovations and breakthroughs in AMD treatments through clinical trials and research initiatives, ensuring that the market continues to evolve in ways that address the specific needs of patients. 

This emphasis on research and development aligns with Japan's commitment to improving healthcare and treatment options, thus fostering a robust environment for the Japan Dry Age-Related Macular Degeneration (AMD) Market to flourish. As the population ages, the focus on these End Users positions them as vital players in tackling the growing prevalence of AMD, responding to the urgent need for effective management strategies.

Japan Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights:

The competitive landscape of the Japan Dry Age-Related Macular Degeneration (AMD) Market is shaped by a combination of established players and emerging companies, all vying for a significant share in a growing sector driven by an aging population and increased awareness of eye health. As the prevalence of AMD steadily rises among the elderly demographic in Japan, pharmaceutical and biopharmaceutical companies are focusing on developing innovative treatments and therapies to address unmet medical needs. Collaboration with healthcare providers and investment in research and development are essential strategic approaches for these companies to differentiate their offerings in this competitive environment. 

The market dynamics are influenced by regulatory approvals, market access strategies, and the effectiveness of the product pipeline, which together define the contours of competition.AbbVie has established a notable presence in the Japan Dry Age-Related Macular Degeneration (AMD) Market, primarily through the development and commercialization of advanced therapeutic options for ophthalmic conditions. The company's robust research initiatives have positioned it well to address the specific needs of AMD patients in Japan, where the demand for effective treatments continues to grow. AbbVie's strengths lie in its extensive experience and expertise in biopharmaceuticals, particularly its strong focus on innovation and patient-centric solutions. 

The company's ability to leverage its existing research capabilities, coupled with strategic partnerships with local entities, enhances its competitive edge, allowing it to navigate the unique regulatory landscape of Japan effectively. This strategic positioning enables AbbVie to remain competitive and responsive to market needs.Bayer also plays a significant role in the Japan Dry Age-Related Macular Degeneration (AMD) Market with its well-regarded portfolio of treatments aimed at managing AMD symptoms and improving patient outcomes. Bayer's key products in this area, including a range of age-related therapies, are backed by substantial clinical data and a commitment to advancing eye health. 

The company's presence in Japan is bolstered by its strong reputation within the pharmaceutical industry, significant investments in research and development, and a proactive approach to merging innovative technologies with patient needs. Bayer’s strengths include a solid distribution network, consistent product quality, and strategic collaborations, which have been instrumental in maintaining its market position. Any recent mergers or acquisitions have also allowed Bayer to enhance its capabilities in ophthalmology and broaden its market reach, positioning the company favorably within the context of AMD treatment advancements in Japan.

Key Companies in the Japan Dry Age-Related Macular Degeneration (AMD) Market Include:

• AbbVie


• Bayer


• Horizon Therapeutics


• Johnson and Johnson


• Genentech


• Roche


• Alcon


• Opthea


• Eyepoint Pharmaceuticals


• Novartis


• Santen Pharmaceutical


• Astellas Pharma


• Eyenovia


• Regeneron Pharmaceuticals


• Apellis Pharmaceuticals

Japan Dry Age-Related Macular Degeneration (AMD) Market Industry Developments

The Japan Dry Age-Related Macular Degeneration (AMD) Market has recently seen significant news developments and changes. In October 2023, Genentech announced progress in their clinical trial regarding innovative treatments for AMD, potentially impacting patient outcomes in Japan. 

Additionally, AbbVie and Horizon Therapeutics have broadened their collaborative efforts to accelerate research in AMD therapies, contributing to the evolving landscape of this market. Major players like Novartis and Roche have reported increased market valuation as a result of heightened demand for AMD treatments amid Japan's aging population. Notable growth in research and development expenditure in the ophthalmic segment, particularly focusing on dry AMD, has been observed, reflecting Japan's commitment to enhancing eye health care. Companies such as Astellas Pharma and Santen Pharmaceutical are aligning their strategies to capture market opportunities, following trends in regenerative treatments. 

Furthermore, in August 2022, Eyenovia announced a strategic partnership with a local firm to enhance the reach of its innovative delivery systems in Japan, thus diversifying treatment modalities in AMD. The collaborative efforts and rising investments have kept the Japanese AMD market dynamic, catering to the growing need for effective treatment solutions in a rapidly aging society.

Japan Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights

• Dry Age-Related Macular Degeneration (AMD) Market Stage Outlook
  
  
  
  • early age-related macular degeneration
  
  
  • intermediate age-related macular degeneration
  
  
  • late age-related macular degeneration
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Age Group Outlook
  
  
  
  • above 75 years
  
  
  • above 60 years
  
  
  • above 40 years
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Outlook
  
  
  
  • treatment
  
  
  • diagnosis
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Outlook
  
  
  
  • oral
  
  
  • injectables
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market End Users Outlook
  
  
  
  • hospitals clinics
  
  
  • diagnostic centers
  
  
  • academic research institutes
  
  
  
  

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	275.0(USD Million)
MARKET SIZE 2024	300.0(USD Million)
MARKET SIZE 2035	900.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	10.503% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	AbbVie, Bayer, Horizon Therapeutics, Johnson and Johnson, Genentech, Roche, Alcon, Opthea, Eyepoint Pharmaceuticals, Novartis, Santen Pharmaceutical, Astellas Pharma, Eyenovia, Regeneron Pharmaceuticals, Apellis Pharmaceuticals
SEGMENTS COVERED	Stage, Age Group, Diagnosis and Treatment, Route of Administration, End Users
KEY MARKET OPPORTUNITIES	Increasing elderly population, Advancements in treatment options, Growth in awareness campaigns, Rising investments in R&D, Development of telehealth solutions
KEY MARKET DYNAMICS	Increasing elderly population, Rising incidence rates, Advancements in treatment options, Growing awareness and education, Expanding healthcare infrastructure
COUNTRIES COVERED	Japan